Grants and Contributions:
Title:
Development of an Inhaled Genetic Medicine for Pre-Exposure Prophylaxis of H5N1 Influenza
Agreement Number:
1037546
Agreement Value:
$764,000.00
Agreement Date:
Nov 3, 2025 - Mar 31, 2026
Description:
Seasonal and pandemic influenza continue to pose substantial threats to public health and highly pathogenic strains such as H5N1 carry the potential for devastating outbreaks. The Firm proposes to develop a novel long-acting pre-exposure prophylaxis platform to deliver DNA-encoded broadly neutralizing antibodies directly to the upper and lower respiratory tracts. This approach aims to provide durable, broad-spectrum protection against influenza infection including emerging avian strains through a single inhaled or intranasal administration.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T5J 4P6
Reference Number:
172-2025-2026-Q3-1037546
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
816561112
Recipient Type:
For-profit organization
Recipient's Legal Name:
Entos Pharmaceuticals Inc.
Federal Riding Name:
Edmonton Centre
Federal Riding Number:
48014
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710